News

Vator Securities rådger Xintela i 40,5 MSEK företrädesemission

Vator Securities agerar som finansiell rådgivare i samband med transaktionen om SEK 40,5 miljoner.

Xintela är en innovatör i utvecklingen avregenerativa cellterapier och riktade cancerterapier baserade på denpatenterade markörteknologiplattformen XINMARK®.

Vator Securities advises LIDDS on 59,3 MSEK Directed and Rights Issue

Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 59,3 million.

LIDDS is a Swedish-based pharmaceutical company which develops new innovative pharmaceutical products with its proprietary drug delivery technology NanoZolid®.

Vator Securities acted as Joint Bookrunner on 400 MSEK Immunovia directed share issue

Vator Securities acted as Joint Bookrunner in connection with the transaction raising SEK 400 million.

Vator Securities was involved in more than two-third of the final allocations to local and international specialist investors, thereby strongly delivering upon the company’s goal to diversify its shareholder base.

Vator Securities advises Xbrane Biopharma on 146 MSEK directed share issue

Vator Securities acted as Global Coordinator and Sole Bookrunner in connection with the transaction raising SEK 146million.

The Directed Share Issue was directed to selected Swedish and international institutional investors, among others, TIN Fonder, Swedbank Robur Ny Teknik and current shareholders Swedbank Robur Medica, STADA Arzneimittel and Serendipity Group among others.

Vator Securities advises NextCell Pharma on 25 MSEK Rights Issue

Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 25 million.

NextCell is a cell therapy company with its leading drug candidate, ProTrans™, a treatment for type 1 diabetes, in a clinical phase II.

Swiss Nordic Bio 2020

Swiss Nordic Bio 2020 was held on 6 February in Zurich and was a collaboration between Vator Securities, the Embassy of Sweden, the Norwegian Embassy, Business Sweden and Business Finland.

Swiss Nordic Bio in Zurich is a high-level partnering and investor event where Swiss and Nordic biotech startups, pharmaceutical companies and investors meet.

Here you will find the film from the event.

Vator Securities advises SciBase on 25 MSEK Rights Issue

Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 25 million.

The capital raised in the rights issue will primarily be used to increase the market presence and penetration of SciBase in the US market where an FDA approval of Nevisense 3.0 is expected during the second quarter of 2020.

Swiss Nordic Bio 2020

Swiss Nordic Bio in Zurich is a high-level partnering and investor event where Swiss and Nordic biotech startups, pharmaceutical companies and investors meet.

Swiss Nordic Bio 2020 will be held on 6 February in Zurich and is a collaboration between Vator Securities, the Embassy of Sweden, the Norwegian Embassy, Business Sweden and Business Finland.